why is semaglutide going away semaglutide - Iscompoundedsemaglutide going away semaglutide Why is Semaglutide Going Away? Understanding the Shift in Compounded Formulations

IscompoundedsemaglutideFDA-approved The landscape of weight loss and diabetes management is constantly evolving, and a significant shift is currently underway regarding semaglutide, a popular GLP-1 receptor agonistSemaglutide officially declared no longer on shortage. Many individuals are asking why is semaglutide going away, particularly concerning compounded versions. The answer lies in the resolution of a prolonged national shortage, coupled with updated regulatory guidance from the U.S. Food and Drug Administration (FDA).

For an extended period starting in 2022, semaglutide injection products, including those marketed under brand names like Ozempic and Wegovy, experienced significant shortages.2025年9月23日—He also points out that Novo Nordisk's US patent onsemaglutideruns out in 2031, while Eli Lilly's expires in 2036. Some companies may make the ... This scarcity was primarily due to increased demand. The high demand placed a strain on the supply chain, prompting many pharmacies to create compounded versions of these medications. These compounded formulations aimed to provide a more accessible and often more affordable alternative for patients who could not obtain the commercially produced drugs.

However, this era is now drawing to a close. The semaglutide shortage is over, officially declared by the FDA on February 21, 2025. This pivotal date signifies a turning point for the availability of the drug. As of this declaration, regulatory bodies and manufacturers are indicating that compounded semaglutide will no longer be produced in the same manner it was during the shortageSemaglutide Alternatives That Support Weight Loss - Midi Health. This means that many of the off-brand or "copycat" versions that became prevalent are now going away.

The FDA's stance has been clarified, stating that once the shortage is resolved, the rationale for compounding these specific formulations diminishes. While compounding pharmacies played a crucial role in ensuring access during the scarcity, the FDA’s policies now emphasize that the drug is no longer on the shortage listFDA crackdown on off-brand Ozempic products set to take .... This has led to restrictions on the mass compounding of semaglutide and other GLP-1 drugs. For example, state-licensed pharmacies were given a deadline, such as April 22, 2025, to cease making most compounded versions designed as copies of Novo Nordisk's Wegovy and Ozempic.

This shift has implications for patients who relied on these more cost-effective options. The FDA's new rule restricting the sale of compounded semaglutide could indeed make it more difficult for some individuals to obtain affordable weight loss medications.2025年4月16日—Online telehealth platform Hims & Hers has confirmed it will keep offering compoundedsemaglutideto eligible patients despite the upcoming FDA restrictions. While the semaglutide shortage on Feb 21, 2025, is a positive development for overall drug availability, it presents a challenge for those who found relief through compounded formulations.

It's important to understand the context of these compounded versions. They were created in response to a critical situation where high demand led to shortages of semaglutide injections. The FDA's concern with unapproved GLP-1 drugs, even those used "for research," also highlights the regulatory scrutiny surrounding these formulations. The agency has warned companies selling unapproved drugs containing semaglutide, tirzepatide, or retatrutide.What you need to know about the compounded GLP-1 ban

While many compounded versions are now being phased out, the market for GLP-1 drugs is complex. Some companies are exploring workarounds, such as offering "personalized" GLP-1 drugs with different dosages or added ingredients. However, these approaches face their own regulatory considerations.Wegovy, Ozempic shortage declared over, hitting copycats ... The original drug manufacturers, like Novo Nordisk, are also working to improve access. For instance, Novo Nordisk announced a significant reduction in the U.S.Are Compounded GLP-1s Going Away? Not Entirely list price for Wegovy®, Ozempic®, and Rybelsus®, effective January 1, 2027, aiming to address access barriers.

The resolution of the semaglutide shortage over marks a win for the accessibility of the approved medications from their original manufacturersSemaglutide Alternatives That Support Weight Loss - Midi Health. However, it necessitates a conversation about alternatives and continued access to effective treatments for conditions like type 2 diabetes and obesity. Patients should consult with their healthcare providers to discuss their individual needs and explore available treatment options, whether they are FDA-approved branded medications, potential future generics as patents expire (e.g.2025年3月14日—The FDA is giving makers of compoundedsemaglutide, the active ingredient in Ozempic and Wegovy, until April 22 to stop making the drug., Novo Nordisk's U.S. patent on semaglutide runs out in 2031, while Eli Lilly's expires in 2036), or other therapies. The focus is shifting back towards regulated and approved pharmaceutical pathways as the supply issues are resolved.